Charles Darwin University

CDU eSpace
Institutional Repository

CDU Staff and Student only

Safe and efficacious artemisinin-based combination treatments for African pregnant women with malaria: a multicentre randomized control trial

Nambozi, Michael, Mulenga, Modest, Halidou, Tinto, Tagbor, Harry, Victor, Mwapasa, Phiri, Linda, Kalanda, Gertrude, Valea, Innocent, Traore, Maminata, Mwakazanga, David, Claeys, Yves, Schurmans, Celine, De Crop, Maaike, Menten, Joris, Ravinetto, Raffaella, Ley-Thriemer, Kamala, Van geertruyden, Jean-Pierre, Mutabingwa, Theonest, D'Alessandro, Umberto and Pregact Group (2015). Safe and efficacious artemisinin-based combination treatments for African pregnant women with malaria: a multicentre randomized control trial. Reproductive Health,12(5).

Document type: Journal Article
Citation counts: Altmetric Score Altmetric Score is 1
Google Scholar Search Google Scholar
Attached Files (Some files may be inaccessible until you login with your CDU eSpace credentials)
Name Description MIMEType Size Downloads
Download this reading LeyThriemer_59107.pdf Published version application/pdf 341.02KB 197
Reading the attached file works best in Firefox, Chrome and IE 9 or later.

IRMA ID 11381xPUB134
Title Safe and efficacious artemisinin-based combination treatments for African pregnant women with malaria: a multicentre randomized control trial
Author Nambozi, Michael
Mulenga, Modest
Halidou, Tinto
Tagbor, Harry
Victor, Mwapasa
Phiri, Linda
Kalanda, Gertrude
Valea, Innocent
Traore, Maminata
Mwakazanga, David
Claeys, Yves
Schurmans, Celine
De Crop, Maaike
Menten, Joris
Ravinetto, Raffaella
Ley-Thriemer, Kamala
Van geertruyden, Jean-Pierre
Mutabingwa, Theonest
D'Alessandro, Umberto
Pregact Group
Journal Name Reproductive Health
Publication Date 2015
Volume Number 12
Issue Number 5
ISSN 1742-4755   (check CDU catalogue open catalogue search in new window)
Scopus ID 2-s2.0-84928685588
Total Pages 10
Place of Publication United Kingdom
Publisher BioMed Central Ltd.
HERDC Category C1 - Journal Article (DIISR)
Abstract Background
Asymptomatic and symptomatic malaria during pregnancy has consequences for both mother and her offspring. Unfortunately, there is insufficient information on the safety and efficacy of most antimalarials in pregnancy. Indeed, clinical trials assessing antimalarial treatments systematically exclude pregnancy for fear of teratogenicity and embryotoxicity. The little available information originates from South East Asia while in sub-Saharan Africa such information is still limited and needs to be provided.

A Phase 3, non-inferiority, multicentre, randomized, open-label clinical trial on safety and efficacy of 4 ACT when administered during pregnancy was carried out in 4 African countries: Burkina Faso, Ghana, Malawi and Zambia. This is a four arm trial using a balanced incomplete block design. Pregnant women diagnosed with malaria are randomised to receive either amodiaquine-artesunate (AQ-AS), dihydroartemisinin-piperaquine (DHA-PQ), artemether-lumefantrine (AL), or mefloquine-artesunate (MQAS). They are actively followed up until day 63 post-treatment and then monthly until 4–6 weeks post-delivery. The offspring is visited at the time of the first birthday. The primary endpoint is treatment failure (PCR adjusted) at day 63 and safety profiles. Secondary endpoints included PCR unadjusted treatment failure up to day 63, gametocyte carriage, Hb changes, placenta malaria, mean birth weight and low birth weight. The primary statistical analysis will use the combined data from all 4 centres, with adjustment for any centre effects, using an additive model for the response rates. This will allow the assessment of all 6 possible pair-wise treatment comparisons using all available data.


The strength of this trial is the involvement of several African countries, increasing the generalisability of the results. In addition, it assesses most ACTs currently available, determining their relative ‘-value-’ compared to others. The balanced incomplete block design was chosen because using all 4-arms in each site would have increased complexity in terms of implementation. Excluding HIV-positive pregnant women on antiretroviral drugs may be seen as a limitation because of the possible interactions between antiretroviral and antimalarial treatments. Nevertheless, the results of this trial will provide the evidence base for the formulation of malaria treatment policy for pregnant women in sub-Saharan Africa.

Trial registration
Keywords Artemisinin-based therapy
Malaria in pregnancy
Pregnant women
DOI   (check subscription with CDU E-Gateway service for CDU Staff and Students  check subscription with CDU E-Gateway in new window)
Additional Notes This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Description for Link Link to CC Attribution 4.0 License

© copyright

Every reasonable effort has been made to ensure that permission has been obtained for items included in CDU eSpace. If you believe that your rights have been infringed by this repository, please contact

Version Filter Type
Access Statistics: 191 Abstract Views, 197 File Downloads  -  Detailed Statistics
Created: Tue, 26 Jul 2016, 12:46:15 CST